TherapeuticsMD, Inc. (TXMD) — Analysis Summary
TherapeuticsMD, Inc. (TXMD) has a market cap of $23.84M with year-over-year revenue growth of +71.6%. Net margin stands at -18.8%. The stock trades at a P/E ratio of -109.9.
Key Takeaways
- Revenue changed +71.6% year-over-year
- Net margin of -18.8%
- P/E ratio of -109.9
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, TXMD posted revenue growth of +71.6% and trades at a P/E of -109.9.
TherapeuticsMD, Inc. (TXMD)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -120.9% — severe operating losses
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
1
Headquarters
BOCA RATON, FL
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.